secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001104659-24-088345
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4
--------------------------------------------------------------------------------

- Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.
- Net loss reduced to $3.4M ($0.17/sh) from $8.4M ($0.46/sh) in Q2 2023.
- Adjusted EBITDA positive $0.3M vs negative $0.6M in prior-year quarter.
- DFD-29 NDA for rosacea under FDA review with PDUFA goal date November 4, 2024.
- Appointed Joseph M. Benesch as permanent CFO and Michael C. Pearce to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924088345/0001104659-24-088345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924088345/tm2421334d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer